The first tau transgenic mouse model was established more than a decade ago. Since then,
much has been learned about the role of tau in Alzheimer's disease and related disorders …

Tauopathies, including Alzheimer's disease, are neurodegenerative diseases characterized
by the deposition of hyperphosphorylated tau protein in the central nervous system, and are …

Advances in genetics and transgenic approaches have a continuous impact on our
understanding of Alzheimer's disease (AD) and related disorders, especially as aspects of …

The two hallmark pathologies of Alzheimer's disease (AD) are amyloid plaques, composed
of the small amyloid‐β (Aβ) peptide, and neurofibrillary tangles, comprised aggregates of the …

Both Alzheimer′ s disease (AD) and frontotemporal dementia (FTD) are characterized by
the deposition of hyperphosphorylated forms of the microtubule‐associated protein tau in …

Accumulation of amyloidogenic proteins such as T au is a hallmark of neurodegenerative
diseases including A lzheimer disease and fronto‐temporal dementias. To link T au …

Filamentous tau aggregates are hallmarks of tauopathies, eg, frontotemporal dementia with
parkinsonism linked to chromosome 17 (FTDP-17) and amyotrophic lateral …

Here, we describe the generation and characterization of a novel tau transgenic mouse
model (mTau) that overexpresses wild-type murine tau protein by twofold compared with …

Several studies have now supported the use of a tau lowering agent as a possible therapy in
the treatment of tauopathy disorders, including Alzheimer's disease. In human Alzheimer's …

Introduction Alzheimer's disease (AD) is a devastating condition with no effective treatments,
with promising findings in rodents failing to translate into successful therapies for patients …